Clinical characteristics of complex aortic plaque in patients with non-valvular atrial fibrillation

详细信息    查看全文

• 作者：Pil-Sung Yang ; Tae-Hoon Kim ; Jae-Sun Uhm ; Jong-Youn Kim ; Boyoung Joung ; Moon-Hyoung Lee ; Hui-Nam Pak ; ^{hnpak@yuhs.ac}
• 关键词：Complex aortic plaque ; CHA2DS2-VASc score ; Atrial fibrillation
• 刊名：International Journal of Cardiology
• 出版年：2017
• 出版时间：1 March 2017
• 年：2017
• 卷：230
• 期：Complete
• 页码：85-90
• 全文大小：596 K
• 卷排序：230

文摘

Although complex aortic plaque (CxAoP) is a component of the CHA2DS2-VASc score in patients with atrial fibrillation (AF), it is underestimated without detection by trans-esophageal echocardiogram (TEE). We have evaluated the incidence and significance of CxAoP among patients with non-valvular AF (NVAF).MethodsWe included 981 patients with NVAF who underwent catheter ablation (59.1 ± 11.1 years old, 73.7% male, 70.2% paroxysmal AF). All of the patients underwent pre-procedural TEE evaluation. Left atrial (LA)-cardioembolic (CE) milieu was defined as a dense spontaneous echo-contrast or LA appendage flow velocity ≤ 20 cm/s.ResultsCxAoP was present in 8.3% of patients, and independently associated with age (OR 1.07, 95% CI 1.03–1.10, p < 0.001), male sex (OR 2.34, 95% CI 1.29–4.24, p = 0.005), and CHA2DS2-VASc score ≥ 2 (OR 3.33, 95%CI 1.42–7.77, p = 0.005). The presence of LA-CE milieu overlapped with CxAoP in only 11% of patients. Patients with CxAoP had a higher prevalence of hypertension (p = 0.004), smoking history (p = 0.008), paroxysmal AF (PAF, p < 0.001), and a smaller LA volume index (p < 0.001) than those with LA-CE milieu. The prevalence of persistent AF among patients with a history of stroke was significantly lower in the presence of CxAoP than in those with LA-CE milieu (p = 0.014). CHA2DS2-VASc score was underestimated in 11% of high-risk patients (CHA2DS2-VASc score ≥ 2) due to undetected CxAoP.ConclusionsCxAoP may contribute to the risk of stroke by a different mechanism than LA-CE milieu in patients with NVAF. Imaging assessment for CxAoP affects thromboembolic risk stratification and decision making for stroke prevention in patients with NVAF.